SOM Biotech and the Anglo-Italian biotech accelerator Inorgen (www.inorgen.com) have successfully reached an agreement to co-develop drug repositioning programs focused mainly on rare diseases. Repositioning and rare diseases are two concepts widely known by both companies. By combining these concepts, costs and time needed to bring the drug onto the market is reduced. Safety risks are also lowered. The extensive network of Inorgen with academia, research institutions and biotech companies, along with the discovery tools and development activities of SOM Biotech makes a unique and promising way to accelerate new treatments from discovery to clinical stage.
In addition, SOM Biotech has also reached a co-development agreement with the Flanders Institute for Biotechnology, VIB ( www.vib.be). Several drug repositioning programs will be carried out.
Este sitio Web utiliza cookies propias para permitir una navegación segura y adaptar el contenido del sitio web. También se usan cookies de terceros para analizar la navegación de los usuarios. No usamos cookies de personalización ni de publicidad. Puede configurar qué tipo de Cookies desea aceptar desde el panel de configuración. Para más información, por favor, visite nuestra Política de Cookies.
This website uses its own cookies to allow safe browsing and adapt the content of the website. Third-party cookies are also used to analyze user browsing. We do not use customization or advertising cookies. You can configure what type of cookies you want to accept from the settings panel. For more information, please visit our Cookies Policy.